How to buy BioXcel Therapeutics stock (BTAI)

BioXcel Therapeutics is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.35 – a decrease of 1.15% over the previous week. BioXcel Therapeutics employs 74 staff and has a trailing 12-month revenue of around $2.4 million.

Our top picks for where to buy BioXcel Therapeutics stock

Buy BioXcel Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

BioXcel Therapeutics stock price (NASDAQ: BTAI)

Use our graph to track the performance of BTAI stocks over time.

BioXcel Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.35
52-week range	$0.33 - $4.17
50-day moving average more info button	$0.55
200-day moving average more info button	$1.34
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.04

Is it a good time to buy BioXcel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioXcel Therapeutics price performance over time

Historical closes compared with the close of $0.3464 from 2024-12-23

1 week (2024-12-18)	-2.48%
1 month (2024-11-25)	-26.30%
3 months (2024-09-25)	-34.17%
6 months (2024-06-25)	-70.64%

1 year (2023-12-22)	-88.57%
2 years (2022-12-23)	-98.42%
3 years (2021-12-23)	22.76
5 years (2019-12-24)	10.1

BioXcel Therapeutics financials

Revenue TTM	$2.4 million
Gross profit TTM	$355,000
Return on assets TTM	-63.62%
Return on equity TTM	-1766.94%
Profit margin	0%
Book value	$-1.89
Market Capitalization more info button	$17.2 million

TTM: trailing 12 months

BioXcel Therapeutics share dividends

We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.

BioXcel Therapeutics share price volatility

Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $0.33 up to $4.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 0.289. This would suggest that BioXcel Therapeutics's shares are less volatile than average (for this exchange).

BioXcel Therapeutics overview

BioXcel Therapeutics, Inc. , a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc.

Frequently asked questions

null
What percentage of BioXcel Therapeutics is owned by insiders or institutions?
Currently 20.063% of BioXcel Therapeutics shares are held by insiders and 8.76% by institutions. How many people work for BioXcel Therapeutics?
Latest data suggests 74 work at BioXcel Therapeutics. When does the fiscal year end for BioXcel Therapeutics?
BioXcel Therapeutics's fiscal year ends in December. Where is BioXcel Therapeutics based?
BioXcel Therapeutics's address is: 555 Long Wharf Drive, New Haven, CT, United States, 06511 What is BioXcel Therapeutics's ISIN number?
BioXcel Therapeutics's international securities identification number is: US09075P1057 What is BioXcel Therapeutics's CUSIP number?
BioXcel Therapeutics's Committee on Uniform Securities Identification Procedures number is: 09075P105